Novavax (NVAX)

Novavax gained global prominence through its COVID-19 vaccine, marketed in various jurisdictions under names including Nuvaxovid and Covovax through partners. The product gives the company a commercial foothold in a vaccine market dominated by larger pharmaceutical groups and mRNA-based competitors. Beyond COVID-19, Novavax works on broader respiratory disease opportunities, including seasonal influenza and combination vaccine candidates that could address multiple respiratory viruses in a single shot.

The company operates as a research-led vaccine developer with manufacturing, regulatory, and commercial partnerships playing an important role in its strategy. Its wholly owned Swedish subsidiary supports production capabilities tied to its adjuvant and vaccine candidates. Novavax also licenses its technology where external partners can use its platform or Matrix-M adjuvant in vaccine programmes, including in areas beyond its core pipeline.

For investors, Novavax represents exposure to a specialist vaccine platform rather than a diversified pharmaceutical business. Its prospects depend on regulatory execution, partner agreements, manufacturing reliability, uptake of existing vaccines, and the ability to convert its technology into durable products for recurring infectious disease markets.